Long-term Outcomes of Mesenchymal Stem Cell Therapy in Severe COVID-19 Patients: 3-year Follow-up of a Randomized, Double-blind, Placebo-controlled Trial

Overview

Journal Stem Cell Res Ther

Publisher Biomed Central

Date 2025 Feb 26

PMID 40001244

Authors

Meng-Qi Yuan

Le Song

Ze-Rui Wang

Zi-Ying Zhang

Ming Shi

Junli He

Qiong Mo

Ning Zheng

Wei-Qi Yao

Yu Zhang

Tengyun Dong

Yuanyuan Li

Chao Zhang

Jinwen Song

Lei Huang

Zhe Xu

Xin Yuan

Jun-Liang Fu

Cheng Zhen

Jianming Cai

Jinghui Dong

Jianzeng Zhang

Wei-Fen Xie

Yonggang Li

Bo Zhang

Lei Shi

Fu-Sheng Wang

Affiliations

Soon will be listed here.

Abstract

Background: The long-term effects and outcomes of human mesenchymal stem cell (MSC) therapy in patients with severe coronavirus disease 2019 (COVID-19) remain poorly understood. This study aimed to evaluate the extended safety and efficacy of MSC treatment in severe patients with COVID-19 who participated in our earlier randomized, double-blind, placebo-controlled clinical trial, with follow-up conducted over 3 years.

Methods: One hundred patients with severe COVID-19 were randomized to receive either an MSC infusion (n = 65, 4 × 10 cells/dose, on days 0, 3, and 6) or a placebo, with both groups receiving the standard of care. At 36 months post-MSC therapy, patients were followed up to long-term safety and efficacy, particularly the effects of MSC therapy on persistent COVID-19 symptoms. Evaluated outcomes included lung imaging results, 6-min walking distance (6-MWD), pulmonary function test results, quality of life scores based on the Short Form-36 (SF-36) health survey, Long COVID symptoms, new-onset comorbidities, tumor marker levels, and rates of COVID-19 reinfection.

Results: Three years post-treatment, 46.94% (23/49) of patients in the MSC group and 34.48% (10/29) in the placebo group showed normal findings on computed tomography (CT) images (odds ratio [OR] = 1.68, 95% confidence interval [CI]: 0.65-4.34). The general health (GH) score from the SF-36 was higher in the MSC group (67.0) compared to the placebo group (50.0), with a difference of 12.86 (95% CI: 1.44-24.28). Both groups showed similar results for total lung severity scores (TSS), 6-MWD, pulmonary function tests, and Long COVID symptoms. No significant differences between groups were observed in new-onset complications (including tumorigenesis) or tumor marker levels. After adjusting for China's dynamic zero-COVID-19 strategy, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reinfection rates were 53.06% (26/49) in the MSC group and 67.86% (19/28) in the placebo group (OR = 0.54, 95% CI: 0.20-1.41).

Conclusions: These findings support the long-term safety of MSC therapy in patients with severe COVID-19 over 3 years. MSC treatment may offer potential benefits for lung recovery and improved quality of life in patients experiencing Long COVID symptoms.

Trial Registration: ClinicalTrials.gov, NCT04288102. Registered 28 February 2020, https://clinicaltrials.gov/study/NCT04288102 .

References

Greenhalgh T, Sivan M, Perlowski A, Nikolich J . Long COVID: a clinical update. Lancet. 2024; 404(10453):707-724. DOI: 10.1016/S0140-6736(24)01136-X. View

Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y . Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020; 382(13):1199-1207. PMC: 7121484. DOI: 10.1056/NEJMoa2001316. View

Shi L, Yuan X, Yao W, Wang S, Zhang C, Zhang B . Human mesenchymal stem cells treatment for severe COVID-19: 1-year follow-up results of a randomized, double-blind, placebo-controlled trial. EBioMedicine. 2021; 75:103789. PMC: 8709782. DOI: 10.1016/j.ebiom.2021.103789. View

Rajala K, Lehto J, Sutinen E, Kautiainen H, Myllarniemi M, Saarto T . mMRC dyspnoea scale indicates impaired quality of life and increased pain in patients with idiopathic pulmonary fibrosis. ERJ Open Res. 2017; 3(4). PMC: 5731772. DOI: 10.1183/23120541.00084-2017. View

. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002; 166(1):111-7. DOI: 10.1164/ajrccm.166.1.at1102. View

Peluso M, Deeks S . Mechanisms of long COVID and the path toward therapeutics. Cell. 2024; 187(20):5500-5529. PMC: 11455603. DOI: 10.1016/j.cell.2024.07.054. View

Li T, Zhang B, Fang H, Shi M, Yao W, Li Y . Human mesenchymal stem cell therapy in severe COVID-19 patients: 2-year follow-up results of a randomized, double-blind, placebo-controlled trial. EBioMedicine. 2023; 92:104600. PMC: 10161678. DOI: 10.1016/j.ebiom.2023.104600. View

Zhang H, Huang C, Gu X, Wang Y, Li X, Liu M . 3-year outcomes of discharged survivors of COVID-19 following the SARS-CoV-2 omicron (B.1.1.529) wave in 2022 in China: a longitudinal cohort study. Lancet Respir Med. 2023; 12(1):55-66. DOI: 10.1016/S2213-2600(23)00387-9. View

. Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950-2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global.... Lancet. 2024; 403(10440):1989-2056. PMC: 11126395. DOI: 10.1016/S0140-6736(24)00476-8. View

10.

Francone M, Iafrate F, Masci G, Coco S, Cilia F, Manganaro L . Chest CT score in COVID-19 patients: correlation with disease severity and short-term prognosis. Eur Radiol. 2020; 30(12):6808-6817. PMC: 7334627. DOI: 10.1007/s00330-020-07033-y. View

11.

Pan F, Yang L, Liang B, Ye T, Li L, Li L . Chest CT Patterns from Diagnosis to 1 Year of Follow-up in Patients with COVID-19. Radiology. 2021; 302(3):709-719. PMC: 8515211. DOI: 10.1148/radiol.2021211199. View

12.

Enright P, Sherrill D . Reference equations for the six-minute walk in healthy adults. Am J Respir Crit Care Med. 1998; 158(5 Pt 1):1384-7. DOI: 10.1164/ajrccm.158.5.9710086. View

13.

Carabelli A, Peacock T, Thorne L, Harvey W, Hughes J, Peacock S . SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nat Rev Microbiol. 2023; 21(3):162-177. PMC: 9847462. DOI: 10.1038/s41579-022-00841-7. View

14.

Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H . Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020; 8(5):475-481. PMC: 7102538. DOI: 10.1016/S2213-2600(20)30079-5. View

15.

Zuo W, He D, Liang C, Du S, Hua Z, Nie Q . The persistence of SARS-CoV-2 in tissues and its association with long COVID symptoms: a cross-sectional cohort study in China. Lancet Infect Dis. 2024; 24(8):845-855. DOI: 10.1016/S1473-3099(24)00171-3. View

16.

Wiersinga W, Rhodes A, Cheng A, Peacock S, Prescott H . Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020; 324(8):782-793. DOI: 10.1001/jama.2020.12839. View

17.

Shi L, Huang H, Lu X, Yan X, Jiang X, Xu R . Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial. Signal Transduct Target Ther. 2021; 6(1):58. PMC: 7873662. DOI: 10.1038/s41392-021-00488-5. View

18.

Lanzoni G, Linetsky E, Correa D, Cayetano S, Alvarez R, Kouroupis D . Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial. Stem Cells Transl Med. 2021; 10(5):660-673. PMC: 8046040. DOI: 10.1002/sctm.20-0472. View

19.

Lim J, Liang En W, Tay A, Pang D, Chiew C, Ong B . Long-term Cardiovascular, Cerebrovascular, and Other Thrombotic Complications in COVID-19 Survivors: A Retrospective Cohort Study. Clin Infect Dis. 2023; 78(1):70-79. PMC: 10810710. DOI: 10.1093/cid/ciad469. View

20.

Bestall J, Paul E, Garrod R, Garnham R, Jones P, Wedzicha J . Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999; 54(7):581-6. PMC: 1745516. DOI: 10.1136/thx.54.7.581. View